APA (7th ed.) Citation

BL, M., A, K., TR, M., N, S., R, N., AW, H., . . . N, A. (2021). Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. The oncologist, 26(12), 1006. https://doi.org/10.1002/onco.13949

Chicago Style (17th ed.) Citation

BL, Maughan, et al. "Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results." The Oncologist 26, no. 12 (2021): 1006. https://doi.org/10.1002/onco.13949.

MLA (9th ed.) Citation

BL, Maughan, et al. "Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results." The Oncologist, vol. 26, no. 12, 2021, p. 1006, https://doi.org/10.1002/onco.13949.